Dec 9, 2005
“Pour yourself a stiff one” Indeed! That’s the word on the pharma lecture circuit as drug companies work themselve up into a lather chasing liquid Viagra.. Meanwhile, there seems to be no end of new targets, even with malaria, cancer, TB, bird flu and the rest providing plenty of fodder, the pharma industry is intent on developing paying treatments for the likes of shyness, hypochondria, and of course premature ejaculation.
Dapoxetine was originally developed as a serotonin-reuptake inhibitor for depression. And, as male users of related quickly, or rather slowly, found out, these drugs cause retarded ejaculation. One man’s side-effect is another man’s therapy. Hence the repositioning, as it were, of Dapoxetine.
Anyway, the industry is, according to Alan Cassels writing in Canada’s CommonGround, keen to get into this new market, although the FDA deigned dapoxetine unapprovable saying that the manufacturer’s claims that it “�increased intra-vaginal ejaculatory latency (IEL) time” better than a placebo, did not stand up to closer examination. So, what will be the next big thing? Have you had enough of my puerile puns and blatant innuendos? Come again for more of the same!